Cargando…

Breast cancer and the black swan

Most current research in cancer is attempting to find ways of preventing patients from dying after metastatic relapse. Driven by data and analysis, this project is an approach to solve the problem upstream, i.e., to prevent relapse. This project started with the unexpected observation of bimodal rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Retsky, Michael, Demicheli, Romano, Hrushesky, William, James, Ted, Rogers, Rick, Baum, Michael, Vaidya, Jayant S, Erhabor, Osaro, Forget, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289621/
https://www.ncbi.nlm.nih.gov/pubmed/32565903
http://dx.doi.org/10.3332/ecancer.2020.1050
_version_ 1783545500075556864
author Retsky, Michael
Demicheli, Romano
Hrushesky, William
James, Ted
Rogers, Rick
Baum, Michael
Vaidya, Jayant S
Erhabor, Osaro
Forget, Patrice
author_facet Retsky, Michael
Demicheli, Romano
Hrushesky, William
James, Ted
Rogers, Rick
Baum, Michael
Vaidya, Jayant S
Erhabor, Osaro
Forget, Patrice
author_sort Retsky, Michael
collection PubMed
description Most current research in cancer is attempting to find ways of preventing patients from dying after metastatic relapse. Driven by data and analysis, this project is an approach to solve the problem upstream, i.e., to prevent relapse. This project started with the unexpected observation of bimodal relapse patterns in breast and a number of other cancers. This was not explainable with the current cancer paradigm that has guided cancer therapy and early detection for many years. After much analysis using computer simulation and input from a number of medical specialties, we eventually came to the conclusion that the surgery to remove the primary tumour produced systemic inflammation for a week after surgery. This systemic inflammation apparently caused exits of cancer cells and micrometastases from dormant states and resulted in relapses in the first 3 years post-surgery. It was determined in a retrospective study that the common inexpensive perioperative non-steroidal anti-inflammatory drug (NSAID) ketorolac could curtail the early relapse events after breast cancer surgery. A second retrospective study strongly confirmed this but an apparently underpowered prospective study showed no advantage. We are analysing these data and are now proposing to test the perioperative NSAID at Beth Israel Deaconess Medical Centre with triple-negative breast cancer (TNBC) patients, the category that could respond best to the perioperative NSAID. If this works as well as we expect, we would then transfer this technology to low- and/or middle-incomes countries (LMICs), starting with Nigeria where early onset type of TNBC is common. There is an unmet need in LMICs, especially in countries like Nigeria (190 million population), for a means to prevent surgery induced relapse that we are attempting to resolve. This work aims, thus, to describe eventual mechanisms, and ways to test a solution addressing an unmet need. But first, we consider the context, including within an historical perspective, important to explain how and why a Kuhnian paradigm shift may be considered.
format Online
Article
Text
id pubmed-7289621
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-72896212020-06-19 Breast cancer and the black swan Retsky, Michael Demicheli, Romano Hrushesky, William James, Ted Rogers, Rick Baum, Michael Vaidya, Jayant S Erhabor, Osaro Forget, Patrice Ecancermedicalscience Review Most current research in cancer is attempting to find ways of preventing patients from dying after metastatic relapse. Driven by data and analysis, this project is an approach to solve the problem upstream, i.e., to prevent relapse. This project started with the unexpected observation of bimodal relapse patterns in breast and a number of other cancers. This was not explainable with the current cancer paradigm that has guided cancer therapy and early detection for many years. After much analysis using computer simulation and input from a number of medical specialties, we eventually came to the conclusion that the surgery to remove the primary tumour produced systemic inflammation for a week after surgery. This systemic inflammation apparently caused exits of cancer cells and micrometastases from dormant states and resulted in relapses in the first 3 years post-surgery. It was determined in a retrospective study that the common inexpensive perioperative non-steroidal anti-inflammatory drug (NSAID) ketorolac could curtail the early relapse events after breast cancer surgery. A second retrospective study strongly confirmed this but an apparently underpowered prospective study showed no advantage. We are analysing these data and are now proposing to test the perioperative NSAID at Beth Israel Deaconess Medical Centre with triple-negative breast cancer (TNBC) patients, the category that could respond best to the perioperative NSAID. If this works as well as we expect, we would then transfer this technology to low- and/or middle-incomes countries (LMICs), starting with Nigeria where early onset type of TNBC is common. There is an unmet need in LMICs, especially in countries like Nigeria (190 million population), for a means to prevent surgery induced relapse that we are attempting to resolve. This work aims, thus, to describe eventual mechanisms, and ways to test a solution addressing an unmet need. But first, we consider the context, including within an historical perspective, important to explain how and why a Kuhnian paradigm shift may be considered. Cancer Intelligence 2020-05-28 /pmc/articles/PMC7289621/ /pubmed/32565903 http://dx.doi.org/10.3332/ecancer.2020.1050 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Retsky, Michael
Demicheli, Romano
Hrushesky, William
James, Ted
Rogers, Rick
Baum, Michael
Vaidya, Jayant S
Erhabor, Osaro
Forget, Patrice
Breast cancer and the black swan
title Breast cancer and the black swan
title_full Breast cancer and the black swan
title_fullStr Breast cancer and the black swan
title_full_unstemmed Breast cancer and the black swan
title_short Breast cancer and the black swan
title_sort breast cancer and the black swan
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289621/
https://www.ncbi.nlm.nih.gov/pubmed/32565903
http://dx.doi.org/10.3332/ecancer.2020.1050
work_keys_str_mv AT retskymichael breastcancerandtheblackswan
AT demicheliromano breastcancerandtheblackswan
AT hrusheskywilliam breastcancerandtheblackswan
AT jamested breastcancerandtheblackswan
AT rogersrick breastcancerandtheblackswan
AT baummichael breastcancerandtheblackswan
AT vaidyajayants breastcancerandtheblackswan
AT erhaborosaro breastcancerandtheblackswan
AT forgetpatrice breastcancerandtheblackswan